177 related articles for article (PubMed ID: 15762885)
1. Assessment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Côte d'Ivoire.
Ondoa P; Koblavi-Dème S; Borget MY; Nolan ML; Nkengasong JN; Kestens L
Clin Exp Immunol; 2005 Apr; 140(1):138-48. PubMed ID: 15762885
[TBL] [Abstract][Full Text] [Related]
2. Changes in levels of immune activation and reconstitution markers among HIV-1-infected Africans receiving antiretroviral therapy.
Koblavi-Dème S; Maran M; Kabran N; Borget MY; Kalou M; Kestens L; Maurice C; Sassan-Morokro M; Ekpini ER; Roels TH; Chorba T; Nkengasong JN
AIDS; 2003 Jul; 17 Suppl 3():S17-22. PubMed ID: 14565605
[TBL] [Abstract][Full Text] [Related]
3. HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: comparison of statistical methods for measurement.
Lubaki NM; Shepherd ME; Brookmeyer RS; Hon H; Quinn TC; Kashamuka M; Johnson M; Gottle R; Devers J; Lederman HM; Bollinger RC
J Acquir Immune Defic Syndr; 1999 Sep; 22(1):19-30. PubMed ID: 10534143
[TBL] [Abstract][Full Text] [Related]
4. Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression.
Zhang JC; Zhang HJ; Li Y; Jing D; Liu Q; Zhao K; Liu QQ; Zhuang Y; Kang WZ; Sun YT
Scand J Infect Dis; 2013 May; 45(5):368-77. PubMed ID: 23186319
[TBL] [Abstract][Full Text] [Related]
5. Association of CD8+ T lymphocyte subsets with the most commonly used markers to monitor HIV type 1 infection in children treated with highly active antiretroviral therapy.
Navarro J; Resino S; Bellón JM; Abad ML; Gurbindo D; Fernández-Cruz E; Muñóz-Fernández MA
AIDS Res Hum Retroviruses; 2001 Apr; 17(6):525-32. PubMed ID: 11350666
[TBL] [Abstract][Full Text] [Related]
6. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.
Hunt PW; Cao HL; Muzoora C; Ssewanyana I; Bennett J; Emenyonu N; Kembabazi A; Neilands TB; Bangsberg DR; Deeks SG; Martin JN
AIDS; 2011 Nov; 25(17):2123-31. PubMed ID: 21881481
[TBL] [Abstract][Full Text] [Related]
7. Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.
d'Ettorre G; Ceccarelli G; Serafino S; Giustini N; Cavallari EN; Bianchi L; Pavone P; Bellelli V; Turriziani O; Antonelli G; Stroffolini T; Vullo V
J Med Virol; 2016 Aug; 88(8):1347-56. PubMed ID: 26765625
[TBL] [Abstract][Full Text] [Related]
8. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
9. Cd38 expression on Cd8+ T cells in Human immunodeficiency virus 1-positive adults treated with HAART.
Beran O; Holub M; Spála J; Kalanin J; Stanková M
Acta Virol; 2003; 47(2):121-4. PubMed ID: 14524479
[TBL] [Abstract][Full Text] [Related]
10. CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection.
Doisne JM; Urrutia A; Lacabaratz-Porret C; Goujard C; Meyer L; Chaix ML; Sinet M; Venet A
J Immunol; 2004 Aug; 173(4):2410-8. PubMed ID: 15294954
[TBL] [Abstract][Full Text] [Related]
11. Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection.
Dyrhol-Riise AM; Voltersvik P; Olofsson J; Asjö B
AIDS; 1999 Dec; 13(17):2365-76. PubMed ID: 10597778
[TBL] [Abstract][Full Text] [Related]
12. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy.
Benito JM; López M; Lozano S; Ballesteros C; Martinez P; González-Lahoz J; Soriano V
J Acquir Immune Defic Syndr; 2005 Apr; 38(4):373-81. PubMed ID: 15764953
[TBL] [Abstract][Full Text] [Related]
13. Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection.
Lange CG; Lederman MM; Madero JS; Medvik K; Asaad R; Pacheko C; Carranza C; Valdez H
J Acquir Immune Defic Syndr; 2002 May; 30(1):33-40. PubMed ID: 12048361
[TBL] [Abstract][Full Text] [Related]
14. Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients.
Bofill M; Mocroft A; Lipman M; Medina E; Borthwick NJ; Sabin CA; Timms A; Winter M; Baptista L; Johnson MA; Lee CA; Phillips AN; Janossy G
AIDS; 1996 Jul; 10(8):827-34. PubMed ID: 8828739
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapy.
Zheng L; Taiwo B; Gandhi RT; Hunt PW; Collier AC; Flexner C; Bosch RJ
J Acquir Immune Defic Syndr; 2014 Oct; 67(2):153-60. PubMed ID: 25072610
[TBL] [Abstract][Full Text] [Related]
16. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study.
Bisset LR; Cone RW; Huber W; Battegay M; Vernazza PL; Weber R; Grob PJ; Opravil M
AIDS; 1998 Nov; 12(16):2115-23. PubMed ID: 9833852
[TBL] [Abstract][Full Text] [Related]
17. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.
Liu Z; Cumberland WG; Hultin LE; Prince HE; Detels R; Giorgi JV
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Oct; 16(2):83-92. PubMed ID: 9358102
[TBL] [Abstract][Full Text] [Related]
18. Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers.
Ganesh A; Lemongello D; Lee E; Peterson J; McLaughlin BE; Ferre AL; Gillespie GM; Fuchs D; Deeks SG; Hunt PW; Price RW; Spudich SS; Shacklett BL
AIDS Res Hum Retroviruses; 2016 Aug; 32(8):791-800. PubMed ID: 27019338
[TBL] [Abstract][Full Text] [Related]
19. Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.
Tilling R; Kinloch S; Goh LE; Cooper D; Perrin L; Lampe F; Zaunders J; Hoen B; Tsoukas C; Andersson J; Janossy G;
AIDS; 2002 Mar; 16(4):589-96. PubMed ID: 11873002
[TBL] [Abstract][Full Text] [Related]
20. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.
Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM
AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
